Evaluation of the Abdala Vaccine: Antibody and Cellular Response to the RBD Domain of SARS-CoV-2

Evaluation of the Abdala Vaccine: Antibody and Cellular Response to the RBD Domain of SARS-CoV-2

Abdala is a recently released RBD protein subunit vaccine against SARS-CoV-2. A few countries, including Mexico, have adopted Abdala as a booster dose in their COVID-19 vaccination schemes. Despite that, most of the Mexican population has received full-scheme vaccination with platforms other than Ab...

Full description

Bibliographic Details
Main Authors: Lorenzo Islas-Vazquez, Yan Carlos Alvarado-Alvarado, Marisa Cruz-Aguilar, Henry Velazquez-Soto, Eduardo Villalobos-Gonzalez, Gloria Ornelas-Hall, Sonia Mayra Perez-Tapia, Maria C. Jimenez-Martinez
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Vaccines
Subjects:
SARS-CoV-2
vaccine
COVID-19
Abdala vaccine
B lymphocytes
T lymphocytes
Online Access:https://www.mdpi.com/2076-393X/11/12/1787

Similar Items

Similar Items